[Medipana] C&R Research achieves a new performance record in the third quarter… Continued operating profit surplus
C&R Research, a contract research organization (CRO), has achieved a new performance record in the third quarter and continues to post a surplus in operating profit since listing.
According to the business report submitted by C&R Research on the 14th, sales in the third quarter were KRW 39.2 billion, up 8% and operating profit by 5% compared to the same period last year. While the recently overheated domestic pharmaceutical and bio investment environment is cooling down, the company is maintaining solid growth and continuing to show good performance.
